XML 63 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and Significant Accounting Policies, Revenue Recognition - Adoption of Topic 606 (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
May 31, 2015
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Consolidated Balance Sheet [Abstract]                          
Current portion of deferred contract revenue   $ 160,256       $ 125,336       $ 160,256 $ 125,336    
Long-term deferred contract revenue   567,359       108,026       567,359 108,026    
Accumulated deficit   (967,293)       (1,241,034)       (967,293) (1,241,034)    
Noncontrolling interest in Akcea Therapeutics, Inc.   139,081       84,267       139,081 84,267    
Total stockholders' equity   1,187,160       365,280       1,187,160 365,280 $ 39,613 $ 200,790
Consolidated Statements of Operations [Abstract]                          
Revenue $ 91,200                 599,674 514,179 372,776  
Income (loss) from operations   10,782 $ (18,572) $ (50,281) $ (3,301) (6,200) $ 11,312 $ 6,450 $ 19,485 (61,372) 31,047 (20,160)  
Net income (loss)   302,735 (20,365) (56,573) (10,812) (9,169) (7,493) (3,085) 8,964 214,985 (10,783) (60,400)  
Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders   320,078 (4,559) (40,358) (1,420) (2,922) (2,611) (3,085) 8,964 273,741 $ 346 $ (60,400)  
Net income (loss) per share, basic and diluted (in dollars per share)                     $ 0.15 $ (0.50)  
Consolidated Statements of Cash Flows [Abstract]                          
Net income (loss)   302,735 $ (20,365) $ (56,573) (10,812) (9,169) $ (7,493) $ (3,085) 8,964 214,985 $ (10,783) $ (60,400)  
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities [Abstract]                          
Deferred contract revenue                   494,254 30,182 (85,306)  
Cash and cash equivalents at beginning of year         129,630       84,685 129,630 84,685 128,797  
Cash and cash equivalents at end of year   $ 278,820       129,630       278,820 129,630 84,685  
Commercial Revenue [Member]                          
Consolidated Statements of Operations [Abstract]                          
Revenue                   254,922 120,014 22,767  
SPINRAZA Royalties [Member]                          
Consolidated Statements of Operations [Abstract]                          
Revenue                   237,930 112,540 883  
Licensing and Other Royalty Revenue [Member]                          
Consolidated Statements of Operations [Abstract]                          
Revenue                   14,755 7,474 21,884  
Research and Development Revenue Under Collaborative Agreements [Member]                          
Consolidated Statements of Operations [Abstract]                          
Revenue                   344,752 394,165 350,009  
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities [Abstract]                          
Increase in revenue from amortization of milestone payments achieved under new revenue guidance                     23,700 24,100  
Decrease in revenue from amortization of payments using input method under new revenue guidance                     (15,100) 0  
Topic 606 [Member]                          
Revenue Recognition [Abstract]                          
Cumulative effect of adoption on retained earnings           (86,100)         (86,100)    
Topic 606 [Member] | As Previously Reported Under Topic 605 [Member]                          
Consolidated Balance Sheet [Abstract]                          
Current portion of deferred contract revenue           106,465         106,465    
Long-term deferred contract revenue           72,708         72,708    
Accumulated deficit           (1,187,398)         (1,187,398)    
Noncontrolling interest in Akcea Therapeutics, Inc.           87,847         87,847    
Total stockholders' equity           418,719         418,719    
Consolidated Statements of Operations [Abstract]                          
Revenue                     507,666 346,620  
Income (loss) from operations                     24,534 (46,316)  
Net income (loss)                     (17,296) (86,556)  
Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders                     $ (5,970) $ (86,556)  
Net income (loss) per share, basic and diluted (in dollars per share)                     $ 0.08 $ (0.72)  
Consolidated Statements of Cash Flows [Abstract]                          
Net income (loss)                     $ (17,296) $ (86,556)  
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities [Abstract]                          
Deferred contract revenue                     36,695 (59,150)  
Cash and cash equivalents at beginning of year         129,630       84,685 129,630 84,685 128,797  
Cash and cash equivalents at end of year           129,630         129,630 84,685  
Topic 606 [Member] | As Previously Reported Under Topic 605 [Member] | Commercial Revenue [Member]                          
Consolidated Statements of Operations [Abstract]                          
Revenue                     122,059 20,722  
Topic 606 [Member] | As Previously Reported Under Topic 605 [Member] | SPINRAZA Royalties [Member]                          
Consolidated Statements of Operations [Abstract]                          
Revenue                     112,540 883  
Topic 606 [Member] | As Previously Reported Under Topic 605 [Member] | Licensing and Other Royalty Revenue [Member]                          
Consolidated Statements of Operations [Abstract]                          
Revenue                     9,519 19,839  
Topic 606 [Member] | As Previously Reported Under Topic 605 [Member] | Research and Development Revenue Under Collaborative Agreements [Member]                          
Consolidated Statements of Operations [Abstract]                          
Revenue                     385,607 325,898  
Topic 606 [Member] | Topic 606 Adjustment [Member]                          
Consolidated Balance Sheet [Abstract]                          
Current portion of deferred contract revenue           18,871         18,871    
Long-term deferred contract revenue           35,318         35,318    
Accumulated deficit           (53,636)         (53,636)    
Noncontrolling interest in Akcea Therapeutics, Inc.           (3,580)         (3,580)    
Total stockholders' equity           (53,439)         (53,439)    
Consolidated Statements of Operations [Abstract]                          
Revenue                     6,513 26,156  
Income (loss) from operations                     6,513 26,156  
Net income (loss)                     6,513 26,156  
Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders                     $ 6,316 $ 26,156  
Net income (loss) per share, basic and diluted (in dollars per share)                     $ 0.07 $ 0.22  
Consolidated Statements of Cash Flows [Abstract]                          
Net income (loss)                     $ 6,513 $ 26,156  
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities [Abstract]                          
Deferred contract revenue                     (6,513) (26,156)  
Cash and cash equivalents at beginning of year         $ 0       $ 0 $ 0 0 0  
Cash and cash equivalents at end of year           $ 0         0 0  
Topic 606 [Member] | Topic 606 Adjustment [Member] | Commercial Revenue [Member]                          
Consolidated Statements of Operations [Abstract]                          
Revenue                     (2,045) 2,045  
Topic 606 [Member] | Topic 606 Adjustment [Member] | SPINRAZA Royalties [Member]                          
Consolidated Statements of Operations [Abstract]                          
Revenue                     0 0  
Topic 606 [Member] | Topic 606 Adjustment [Member] | Licensing and Other Royalty Revenue [Member]                          
Consolidated Statements of Operations [Abstract]                          
Revenue                     (2,045) 2,045  
Topic 606 [Member] | Topic 606 Adjustment [Member] | Research and Development Revenue Under Collaborative Agreements [Member]                          
Consolidated Statements of Operations [Abstract]                          
Revenue                     $ 8,558 $ 24,111